Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.70 | 21.10 | -0.24% |
| CAC 40 | 7,807.87 | 162.01 | -2.03% |
| DAX 40 | 22,839.56 | 662.69 | -2.82% |
| Dow JONES (US) | 46,052.46 | 172.69 | -0.37% |
| FTSE 100 | 10,063.50 | 241.79 | -2.35% |
| HKSE | 25,500.58 | 524.84 | -2.02% |
| NASDAQ | 22,085.62 | 66.80 | -0.30% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 13,000.86 | 314.74 | -2.36% |
| S&P 500 | 6,606.30 | 18.40 | -0.28% |
| S&P/ASX 200 | 8,497.80 | 7.60 | -0.09% |
| SSE Composite Index | 4,006.55 | 56.43 | -1.39% |